Immunic, Inc. (NASDAQ:IMUX) Shares Acquired by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Immunic, Inc. (NASDAQ:IMUX) by 90.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,579 shares of the company’s stock after acquiring an additional 96,894 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.23% of Immunic worth $205,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Invesco Ltd. bought a new stake in shares of Immunic in the 4th quarter worth about $37,000. HB Wealth Management LLC acquired a new position in Immunic in the fourth quarter worth about $81,000. Barclays PLC bought a new stake in Immunic in the fourth quarter valued at about $84,000. Jane Street Group LLC raised its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after buying an additional 22,200 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Stock Performance

IMUX stock opened at $0.98 on Thursday. Immunic, Inc. has a 1 year low of $0.83 and a 1 year high of $2.11. The stock has a market capitalization of $93.63 million, a price-to-earnings ratio of -0.79 and a beta of 1.73. The stock’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.09.

Analysts Set New Price Targets

Several brokerages have recently commented on IMUX. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, April 30th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. William Blair began coverage on shares of Immunic in a research report on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, B. Riley reaffirmed a “buy” rating and issued a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic has a consensus rating of “Buy” and a consensus price target of $13.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.